QQQ   303.72 (+0.04%)
AAPL   152.15 (+0.28%)
MSFT   262.04 (+2.05%)
META   188.42 (+1.27%)
GOOGL   104.32 (+1.38%)
AMZN   98.96 (-3.15%)
TSLA   192.57 (-1.12%)
NVDA   213.55 (+1.26%)
NIO   10.74 (-1.74%)
BABA   105.00 (-0.43%)
AMD   83.64 (-0.05%)
T   19.35 (-1.17%)
F   13.05 (-0.68%)
MU   60.32 (+0.57%)
CGC   2.84 (-3.73%)
GE   81.18 (-1.42%)
DIS   109.56 (-0.28%)
AMC   6.27 (-7.79%)
PFE   43.71 (-0.11%)
PYPL   81.84 (-0.60%)
NFLX   358.04 (-0.95%)
QQQ   303.72 (+0.04%)
AAPL   152.15 (+0.28%)
MSFT   262.04 (+2.05%)
META   188.42 (+1.27%)
GOOGL   104.32 (+1.38%)
AMZN   98.96 (-3.15%)
TSLA   192.57 (-1.12%)
NVDA   213.55 (+1.26%)
NIO   10.74 (-1.74%)
BABA   105.00 (-0.43%)
AMD   83.64 (-0.05%)
T   19.35 (-1.17%)
F   13.05 (-0.68%)
MU   60.32 (+0.57%)
CGC   2.84 (-3.73%)
GE   81.18 (-1.42%)
DIS   109.56 (-0.28%)
AMC   6.27 (-7.79%)
PFE   43.71 (-0.11%)
PYPL   81.84 (-0.60%)
NFLX   358.04 (-0.95%)
QQQ   303.72 (+0.04%)
AAPL   152.15 (+0.28%)
MSFT   262.04 (+2.05%)
META   188.42 (+1.27%)
GOOGL   104.32 (+1.38%)
AMZN   98.96 (-3.15%)
TSLA   192.57 (-1.12%)
NVDA   213.55 (+1.26%)
NIO   10.74 (-1.74%)
BABA   105.00 (-0.43%)
AMD   83.64 (-0.05%)
T   19.35 (-1.17%)
F   13.05 (-0.68%)
MU   60.32 (+0.57%)
CGC   2.84 (-3.73%)
GE   81.18 (-1.42%)
DIS   109.56 (-0.28%)
AMC   6.27 (-7.79%)
PFE   43.71 (-0.11%)
PYPL   81.84 (-0.60%)
NFLX   358.04 (-0.95%)
QQQ   303.72 (+0.04%)
AAPL   152.15 (+0.28%)
MSFT   262.04 (+2.05%)
META   188.42 (+1.27%)
GOOGL   104.32 (+1.38%)
AMZN   98.96 (-3.15%)
TSLA   192.57 (-1.12%)
NVDA   213.55 (+1.26%)
NIO   10.74 (-1.74%)
BABA   105.00 (-0.43%)
AMD   83.64 (-0.05%)
T   19.35 (-1.17%)
F   13.05 (-0.68%)
MU   60.32 (+0.57%)
CGC   2.84 (-3.73%)
GE   81.18 (-1.42%)
DIS   109.56 (-0.28%)
AMC   6.27 (-7.79%)
PFE   43.71 (-0.11%)
PYPL   81.84 (-0.60%)
NFLX   358.04 (-0.95%)
NASDAQ:ESPR

Esperion Therapeutics - ESPR Stock Forecast, Price & News

$5.96
+0.14 (+2.41%)
(As of 02/7/2023 10:28 AM ET)
Add
Compare
Today's Range
$5.72
$5.96
50-Day Range
$5.09
$7.49
52-Week Range
$3.28
$8.87
Volume
169,381 shs
Average Volume
1.45 million shs
Market Capitalization
$439.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.20

Esperion Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
92.4% Upside
$11.20 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
0.18mentions of Esperion Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$52,754 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.65) to ($1.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

373rd out of 1,027 stocks

Pharmaceutical Preparations Industry

187th out of 500 stocks

ESPR stock logo

About Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Stock News Headlines

Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Morgan Stanley
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
H.C. Wainwright Reaffirms Their Buy Rating on Esperion (ESPR)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Esperion to Participate in January Investor Meetings
Esperion (ESPR) Reports Positive Data From CLEAR Study
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
Esperion Appoints Ben Halladay Chief Financial Officer
Recap: Esperion Therapeutics Q3 Earnings
See More Headlines
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Company Calendar

Last Earnings
11/02/2021
Today
2/07/2023
Next Earnings (Estimated)
2/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
218
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.20
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+87.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-269,110,000.00
Net Margins
-337.63%
Pretax Margin
-337.63%

Debt

Sales & Book Value

Annual Sales
$78.45 million
Book Value
($3.23) per share

Miscellaneous

Free Float
71,252,000
Market Cap
$439.13 million
Optionable
Optionable
Beta
0.21

Key Executives

  • Sheldon L. Koenig
    President, Chief Executive Officer & Director
  • Benjamin Halladay
    Chief Financial Officer
  • Ken Fiorelli
    Chief Technical Operations Officer
  • JoAnne Micale Foody
    Chief Medical Officer
  • William J. Sasiela
    Senior Vice President-Clinical Development













ESPR Stock - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings
or view top-rated stocks.

What is Esperion Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $6.00 to $22.00. On average, they predict the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 92.4% from the stock's current price.
View analysts price targets for ESPR
or view top-rated stocks among Wall Street analysts.

How have ESPR shares performed in 2023?

Esperion Therapeutics' stock was trading at $6.23 at the beginning of the year. Since then, ESPR stock has decreased by 6.6% and is now trading at $5.82.
View the best growth stocks for 2023 here
.

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our ESPR earnings forecast
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.62) earnings per share for the quarter, topping analysts' consensus estimates of ($2.86) by $0.24. The biopharmaceutical company earned $14.41 million during the quarter, compared to analyst estimates of $12.31 million. During the same quarter last year, the business posted ($3.07) EPS.

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Monaco Asset Management SAM (0.64%), Simplex Trading LLC (0.00%), Pinnacle Associates Ltd. (0.33%), Pinnacle Associates Ltd. (0.32%), Wolverine Asset Management LLC (0.12%) and Daiwa Securities Group Inc. (0.05%). Insiders that own company stock include Benjamin Looker, Eric Warren, Joanne M Foody, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends
.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $5.82.

How much money does Esperion Therapeutics make?

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $428.82 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269,110,000.00 in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

The company employs 218 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.

This page (NASDAQ:ESPR) was last updated on 2/7/2023 by MarketBeat.com Staff